Lacosamida Alter

Lacosamide, the active ingredient in Lacosamida Alter, is a sodium channel blocker presented as an oral tablet for oral administration. It is used to control partial‑onset seizures in adults and children with epilepsy, helping to reduce seizure frequency and improve quality of life.

GNH USA supplies Lacosamida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under strict GMP conditions.

Lacosamide is an antiepileptic medication that targets neuronal sodium channels to manage seizure disorders.

Partial‑onset seizures: reduces seizure frequency in patients with epilepsy. Adjunct therapy for refractory epilepsy: used alongside other antiepileptics when seizures persist. Focal seizures in adults and children: helps achieve better seizure control.

Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Nausea: feeling of queasiness or urge to vomit. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Cardiac conduction abnormalities: prolongation of the PR interval, potentially leading to arrhythmia. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

Lacosamide requires careful monitoring in several clinical situations. - Renal impairment: dose adjustments may be necessary. - Cardiac conduction: monitor PR interval, especially when combined with other agents affecting cardiac rhythm. - Hepatic disease: use caution and monitor liver function tests. - Pregnancy and breastfeeding: limited data; weigh benefits against potential risks. - Abrupt discontinuation: may increase seizure frequency; taper gradually under medical supervision. - Store below 25°C: keep in the original packaging, protect from moisture.

Lacosamide may interact with various medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may lower lacosamide plasma levels. - Other sodium channel blockers (e.g., phenytoin): increased risk of neurotoxicity. - Drugs that prolong PR interval (e.g., beta‑blockers): may exacerbate cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Co‑administration with other antiepileptics (e.g., valproate): may require dose adjustments. - Oral contraceptives: lacosamide may reduce contraceptive effectiveness. - Alcohol: can enhance central nervous system depression.